Cargando…
Single-Dose Treatment with Rapamycin Preserves Post-Ischemic Cardiac Function through Attenuation of Fibrosis and Inflammation in Diabetic Rabbit
Robust activation of mTOR (mammalian target of rapamycin) signaling in diabetes exacerbates myocardial injury following lethal ischemia due to accelerated cardiomyocyte death with cardiac remodeling and inflammatory responses. We examined the effect of rapamycin (RAPA, mTOR inhibitor) on cardiac rem...
Autores principales: | Samidurai, Arun, Saravanan, Manu, Ockaili, Ramzi, Kraskauskas, Donatas, Lau, Suet Ying Valerie, Kodali, Varun, Ramasamy, Shakthi, Bhoopathi, Karthikeya, Nair, Megha, Roh, Sean K., Kukreja, Rakesh C., Das, Anindita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218967/ https://www.ncbi.nlm.nih.gov/pubmed/37240345 http://dx.doi.org/10.3390/ijms24108998 |
Ejemplares similares
-
Preclinical model of type 1 diabetes and myocardial ischemia/reperfusion injury in conscious rabbits—demonstration of cardioprotection with rapamycin
por: Samidurai, Arun, et al.
Publicado: (2021) -
Differential Regulation of mTOR Complexes with miR-302a Attenuates Myocardial Reperfusion Injury in Diabetes
por: Samidurai, Arun, et al.
Publicado: (2020) -
Reperfusion Therapy with Rapamycin Attenuates Myocardial Infarction through Activation of AKT and ERK
por: Filippone, Scott M., et al.
Publicado: (2017) -
Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases
por: Samidurai, Arun, et al.
Publicado: (2018) -
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine—a possible prevention strategy for COVID-19?
por: Kukreja, Rakesh C., et al.
Publicado: (2022)